Drug Interactions between famotidine and Uptravi
This report displays the potential drug interactions for the following 2 drugs:
- famotidine
- Uptravi (selexipag)
Interactions between your drugs
No interactions were found between famotidine and Uptravi. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
famotidine
A total of 298 drugs are known to interact with famotidine.
- Famotidine is in the drug class H2 antagonists.
-
Famotidine is used to treat the following conditions:
- Allergic Urticaria (off-label)
- Cutaneous Mastocytosis
- Duodenal Ulcer
- Duodenal Ulcer Prophylaxis
- Erosive Esophagitis
- GERD
- Hiatal Hernia (off-label)
- Indigestion
- Laryngopharyngeal Reflux (off-label)
- Pathological Hypersecretory Conditions
- Peptic Ulcer
- Stomach Ulcer
- Upper GI Hemorrhage
- Urticaria (off-label)
- Zollinger-Ellison Syndrome
Uptravi
A total of 230 drugs are known to interact with Uptravi.
- Uptravi is in the drug class agents for pulmonary hypertension.
- Uptravi is used to treat Pulmonary Arterial Hypertension.
Drug and food interactions
selexipag food
Applies to: Uptravi (selexipag)
Food prolongs the gastrointestinal absorption of selexipag. When taken with food, the time to peak concentration (Tmax) was delayed and peak plasma concentration (Cmax) was approximately 30% lower. Selexipag systemic exposure (AUC) and that of its active metabolite did not significantly change, however. Selexipag may be taken with or without food. Tolerability may be improved when taken with food.
References
- (2016) "Product Information. Uptravi (selexipag)." Actelion Pharmaceuticals US Inc
famotidine food
Applies to: famotidine
H2 antagonists may reduce the clearance of nicotine. Cimetidine, 600 mg given twice a day for two days, reduced clearance of an intravenous nicotine dose by 30%. Ranitidine, 300 mg given twice a day for two days, reduced clearance by 10%. The clinical significance of this interaction is not known. Patients should be monitored for increased nicotine effects when using the patches or gum for smoking cessation and dosage adjustments should be made as appropriate.
References
- Bendayan R, Sullivan JT, Shaw C, Frecker RC, Sellers EM (1990) "Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans." Eur J Clin Pharmacol, 38, p. 165-9
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.